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Abstract
Prolyl 4-hydroxylase catalyzes the hydroxylation of collagen pro-K chains for the deposition of cardiac collagen. The effect
of prolyl 4-hydroxylase on synthesis and degradation of collagen was studied in cultured adult cardiac fibroblasts using
mimosine, a prolyl 4-hydroxylase inhibitor. Mimosine inhibited [3H]thymidine incorporation in cultured fibroblasts in a
dose-dependent manner (100^600 WM). Immunofluorescence in fibroblasts and biochemical detection of mature type I
collagen in culture serum revealed a strong inhibition of synthesis and secretion of mature collagens, respectively, in the
presence of 200 WM mimosine. Western blot analysis for procollagen was carried out in cultured fibroblasts, and 200 WM
mimosine treatment was associated with increased intracellular accumulation of procollagen from 4.14 þ 0.27 to 10.19 þ 0.37
(arbitrary units). Immunofluorescence studies confirmed a marked increase of intracellular procollagens in fibroblasts treated
with mimosine, which suggests a loss of coordinated monomeric procollagen synthesis and secretion of triple helical mature
collagens. Modest inhibition of collagen type I mRNA abundance was observed in mimosine-treated fibroblasts, whereas no
effect was noted for mRNAs of collagen type III, K-prolyl 4-hydroxylase or L-prolyl 4-hydroxylase when compared to
untreated control values. Treatment of fibroblasts with 200 WM mimosine was associated with elevation of matrix
metalloproteinase (MMP)-9 activity. The cytotoxicity of mimosine treatment was found minimal at the concentrations
indicated above. Thus the antifibrotic effects induced by mimosine on cultured adult cardiac fibroblasts was associated with
inhibition of prolyl 4-hydroxylase and diminished extracellular secretion of procollagen, despite the reactive elevation of
intracellular procollagen synthesis. We suggest that specific inhibition of prolyl 4-hydroxylase may provide a novel
therapeutic approach for the modulation of cardiac fibrosis. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
In the heart, cardiac myocytes occupy V75% of
the total myocardial volume, but represent only one-
third of the total cardiac cell population. Cardiac
non-myocytes reside mainly in the cardiac interstiti-
um and account for the remaining two-thirds of the
total cell population [1]. Cardiac ¢broblasts exist in
large numbers in the heart and form the largest
group among cardiac non-myocyte cells. Produced
mainly by cardiac ¢broblasts and ¢broblast deriva-
tives i.e. myo¢broblasts, ¢brillar collagen types I and
III are major forms of cardiac collagen and represent
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more than 90% of this class of protein within the
myocardium [1]. Type I collagen has the approximate
tensile strength of steel and accounts for V75% of
total collagen in the adult myocardium; type III col-
lagen comprises V15% of all collagen and is more
distensible than type I collagen [1]. Cardiac ¢brosis,
characterized by the accumulation of collagen depos-
ited in the interstitium of myocardium, is implicated
in the development of cardiac dysfunction in essen-
tial hypertension and after myocardial infarction
(post-MI) [2^4]. Recent experimental data suggests
that cardiac collagen remodeling may contribute to
the development of cardiac hypertrophy and heart
failure [5^7].
Trimeric ¢brillar collagens may be regulated at
transcriptional (mRNA), translational (monomeric
pro-K chains) and post-translational levels. The latter
pathway is well characterized, and prolyl 4-hydrox-
ylase is known to be a key enzyme responsible for
the post-translational processing of collagen pro-K
chain monomer [8]. Speci¢cally, prolyl 4-hydroxylase
catalyzes the hydroxylation of speci¢c proline resi-
dues on collagen pro-K chains facilitating the self-
assembly of the triple stranded helical procollagen
molecule and it potentiates the subsequent secretion
of procollagen into the extracellular space [8]. The
active prolyl 4-hydroxylase is a tetramer (K2L2)
with a molecular weight of approximately 240 kDa
[9]. It has been reported that a signi¢cant proportion
(36^96%) of newly synthesized procollagen is rou-
tinely degraded upon its translation in both normal
and hypertrophic hearts [10], and discoordination
between collagen gene activation events and collagen
deposition has been reported in aging rats [11]. We
have previously observed that collagen mRNA abun-
dance was maximally increased in rat hearts at
1-week post-MI, but that collagen protein accumu-
lates progressively in this experimental model at
times beyond this stage [12]. This evidence suggests
that complex post-translational modi¢cation(s) of
collagen synthesis are important control points for
cardiac collagen deposition in both physiological
and pathological conditions in vivo.
The importance of prolyl hydroxylation in the reg-
ulation of collagen synthesis was also demonstrated
in vitro using cultured neonatal cardiac ¢broblasts
[13]. Ascorbic acid, a co-factor of prolyl 4-hydroxy-
lase, signi¢cantly stimulated hydroxyproline synthe-
sis, but had no e¡ect on mRNA abundance of colla-
gen type I and type III [13]. Conversely, the
degradation of newly synthesized procollagen was
signi¢cantly increased in ascorbic acid-de¢cient ¢bro-
blasts [13]. Inhibition of prolyl 4-hydroxylase by 3,4-
dihydroxybenzoic acid is known to cause intracellu-
lar accumulation of procollagen [13]. L-Mimosine, a
naturally occurring catechol analog, has been shown
to inhibit DNA synthesis at the level of elongation of
nascent chains by altering deoxyribonucleotide me-
tabolism, and is an inhibitor of prolyl 4-hydroxylase
[14]. For example, using cultured smooth muscle cells
from human primary atherosclerotic and restenotic
coronaries, 50 WM mimosine has been shown to com-
pletely inhibit puri¢ed prolyl 4-hydroxylase activity
[15]. However, the precise role of prolyl 4-hydroxy-
lase in regulating collagen production in adult car-
diac ¢broblasts remains unclear. The goal of the cur-
rent study is to determine the role of hydroxylation
on mature cardiac collagen production from adult
cardiac ¢broblasts, and to investigate the e¡ect of
mimosine on cardiac collagen metabolism. Speci¢-
cally, we determined the e¡ects of mimosine on (1)
cardiac ¢broblast proliferation; (2) mature trimeric
collagen synthesis and secretion and whether those
e¡ects were coordinated with altered intracellular
procollagen synthesis; (3) mRNA abundance of col-
lagen and prolyl 4-hydroxylase; and (4) matrix met-
alloproteinase (MMP) activity in cultured adult rat
cardiac ¢broblasts.
2. Materials and methods
2.1. Adult cardiac ¢broblast isolation and culture
Adult cardiac ¢broblasts were isolated from male
Sprague^Dawley rats according to the methods of
Brilla et al. [16]. In brief, rats were anesthetized
with a mixture of ketamine and xylazine (100:10
mg/kg, respectively) and then heparinized (200
U/100 g b.wt.). The heart was subjected to Langen-
dor¡ perfusion at a £ow of 5 ml/min at 35‡C ¢rst
with calcium free Joklik’s medium for 5 min and
then with recirculatory Joklik’s medium containing
0.1% collagenase and 2% bovine serum albumin
(BSA) for 25^35 min. The perfusate containing cor-
onary endothelia and smooth muscle cells was dis-
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carded. The ventricular tissues were further digested
in a shaking £ask with 5 ml Joklik’s medium con-
taining 0.05% collagenase and 1% BSA for 10 min.
The liberated cells were collected by centrifugation at
2000 rpm for 10 min. The cell pellet was resuspended
in Dulbecco’s modi¢ed Eagle’s medium F-12. Fol-
lowing this, the suspension was plated on a 100
mm non-coated culture £ask at 37‡C with 5% CO2
for 2 h. Cardiac ¢broblasts attached to the bottom of
culture £ask during 2 h incubation while non-adher-
ent myocytes were removed by changing the culture
medium. The cells were maintained in DMEM/F-12
supplemented with 10% fetal bovine serum, 100 U/ml
penicillin, 100 Wg/ml streptomycin and 100 WM as-
corbic acid. All experiments were performed in se-
rum-free conditions unless stated otherwise. The cells
used for the study were from the second passage
(P2). Routine phenotyping of the cells isolated
from this experiment was carried out using monoclo-
nal antibody against desmin (smooth muscle cells)
and monoclonal antibody against factor VIII (specif-
ic to endothelial cells). As the possibility that cardiac
myo¢broblasts may also exist in our cultures, in a
separate set of experiments we double-stained cells
for K-smooth muscle actin (K-SMA) and desmin.
Cells positive for K-SMA and negative for desmin
were labeled as myo¢broblasts. We found that the
purity of ¢broblasts in these experiments was v 95%.
2.2. DNA synthesis
Cells were plated onto 24-well culture plates and
allowed to attach for 24 h. Mimosine (Aldrich) treat-
ment was carried out in both serum (10%) and se-
rum-free conditions. Mimosine was dissolved in
20 mM NaOH at a concentration of 40 mM. This
stock solution was sterilized by ¢ltration through a
0.20 Wm ¢lter, and stored at 320‡C. DNA incorpo-
ration was measured according to the methods of
Saward et al. [17]. To measure DNA synthesis,
both mimosine and [3H]thymidine were added to
the cardiac ¢broblast cultures in 24-well plates. Fol-
lowing 24 h incubation at 37‡C, the cells were lysed
for 30 min with lysis bu¡er containing 0.1 M Tris-
HCl (pH 7.4), 0.5% sodium dodecyl sulfate, 0.1 M
NaCl, and 10 mM ethylene diaminetetraacetic acid.
The incorporated label was precipitated using an
equal volume of 20% trichloroacetic acid (TCA).
Samples were ¢ltered through GF/A ¢lters and
rinsed three times with 5% TCA followed by a 95%
ethanol rinse. Filters were allowed to dry at 50‡C for
30 min. Scintillation £uid (4 ml) was added to each
sample and the count was determined using a scin-
tillation counter (Beckman LS 6500, Fullerton, CA,
USA).
2.3. LDH activity
Cardiac ¢broblasts were treated with di¡erent
doses of mimosine (25^800 WM) after 24 h serum-
free conditioning. The release of lactate dehydrogen-
ase (LDH) in culture medium was determined using
a commercial kit (Sigma, St. Louis, MO, USA) ac-
cording to the methods of the manufacturer.
2.4. Immuno£uorescence assay
Adult cardiac ¢broblasts were plated on coverslips
and allowed to grow for 24 h. Cells were ¢xed with
1% paraformaldehyde after 24 h treatment with 200
WM mimosine. Immuno£uorescent staining was per-
formed by the indirect immuno£uorescence techni-
que [18] to detect mature collagen type I and procol-
lagen type I. Cells were incubated with polyclonal
anti-type I collagen antibody (Southern Biotechnol-
ogy, Alabama, USA) or monoclonal antibody
against procollagen type I (SP1.D8 ^ Developmental
Studies Hybridoma Bank, University of Iowa, USA)
and incubated overnight at 4‡C. The primary anti-
bodies were diluted (1:100 for collagen and 1:20 for
procollagen) with phosphate-bu¡ered saline (PBS)
containing 1% BSA. After washing with PBS, cells
were incubated with biotinylated anti-goat IgG sec-
ondary antibody followed by incubation with Texas
red-labeled streptavidin to detect mature collagen,
while for the detection of procollagen cells were in-
cubated with anti-mouse linked Texas red conjugate
(1:20 with 1% BSA in PBS, Amersham Life Sciences,
Canada). After washing (3U5 min) with cold PBS,
some sections were immersed for 30 s in 10 Wg/ml of
Hoechst Dye 33342 in order to stain cellular nuclei,
and then subjected to an additional wash (3U5 min)
in cold PBS. The slides were examined under a mi-
croscope equipped with epi£uorescence optics, pho-
tographed on Kodak TMAX 400 black and white
¢lm.
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2.5. Hydroxyproline assay
After 24 h treatment of cells with 200 WM mimo-
sine, the culture medium was collected. Hydroxypro-
line concentration in the culture medium was meas-
ured according to the method of Chiariello et al. [19]
using 4-hydroxyproline (Sigma Aldrich) as standard.
Total protein concentration was measured using the
BCA method [20]. The result was expressed as Wg/mg
total protein in the medium.
2.6. Western blot
Intracellular accumulation of procollagen type I
was detected using Western blot. Cardiac ¢broblasts
were scraped o¡ culture plates in 1 ml 100 mM Tris
(pH 7.4) containing 1 mM EDTA, 1 mM PMSF,
4 WM leupeptin, 1 WM pepstatin A and 0.3 WM apro-
tinin after 24 h treatment with 200 WM mimosine.
Cells were sonicated and total protein concentration
was assayed using the BCA method [20]. Prestained
high molecular weight marker (Bio-Rad, USA) and
20 Wg protein sample were separated on 5% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE). The separated proteins were trans-
ferred to 0.45 WM nitrocellulose. The membrane
was blocked at 4‡C overnight and probed with pri-
mary antibody SP1.D8, a monoclonal antibody spe-
ci¢c for the amino terminal cleavage site of procol-
lagen type I (Developmental Studies Hybridoma
Bank, University of Iowa, USA) [21]. The secondary
antibody was horseradish peroxidase (HRP)-labeled
anti-mouse IgG. Procollagen type I was visualized by
enhanced chemiluminescence (ECL) (Amersham Life
Science, Canada). Results of autoradiographs from
Western blot were quanti¢ed using a CCD camera
imaging densitometer (Bio-Rad GS 670, USA).
2.7. RNA extraction and Northern blot analysis
Total RNA was isolated from mimosine-treated
and -untreated cardiac ¢broblasts by the method of
Chomczynski and Sacchi [22]. Total RNA was dis-
solved in diethyl pyrocarbonate (DEPC) treated
water and absorbances were taken at 260 and 280
nm. The total RNA concentration was calculated
based on the absorbance at 260 nm. Twenty Wg of
RNA was electrophoresed in a 1% agarose/formalde-
hyde gel, and the fractionated RNA was transferred
to a positively charged nylon membrane. The mem-
branes were then hybridized with collagen types I
[23], III [24], K-prolyl 4-hydroxylase, L-prolyl 4-hy-
droxylase, and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) [25] cDNA probes. The cDNA
probes for collagen type I, III and GAPDH were
purchased from America Type Culture Collection.
The cDNA probes for human K-prolyl 4-hydroxylase
and L-prolyl 4-hydroxylase were generous gifts from
Drs. T. Helaakoski and T. Pihlajaniemi at the Uni-
versity of Oulu, Finland. The cDNA probes were
labeled with 32P using a random primer labeling kit
(Gibco-BRL). All probes have speci¢c activity s 109
cpm per Wg DNA. Results of autoradiographs from
Northern blot were quanti¢ed using a CCD camera
imaging densitometer (Bio-Rad GS 670, USA). The
ratio of signal of speci¢c mRNA to GAPDH was
used to normalize for di¡erences in loading and/or
transfer of mRNA.
2.8. Zymography
MMP activity in culture medium was detected by
gelatinolytic zymography [26]. Gelatin can be readily
cleaved by MMPs and easily incorporated into poly-
acrylamide gels. Gelatin (¢nal concentration 1 mg/
ml) was added to a 7.5% standard SDS-PAGE.
Twenty Wg of protein was loaded per lane without
reduction or boiling and samples were run at 15 mA
per gel. After electrophoresis, gels were washed
2U15 min in 25 mM glycine (pH 8.3), 2.5% Triton
X-100 with gentle shaking at 4‡C to eliminate SDS
from the gels. Once rinsed, the gels were incubated at
37‡C for 16 h in substrate bu¡er (50 mM Tris-HCl,
pH 8.0, 5 mM CaCl2). After incubation, the gels
were stained in 0.05% Coomassie blue (R-250) for
30 min, and then destained in acetic acid and meth-
anol. Gels were then dried and scanned using a CCD
camera imaging densitometer (Bio-Rad GS 670,
USA). The MMP activity was veri¢ed using the
MMP inhibitor 1,10-phenanthroline, a chelator
known to inhibit all gelatinolytic activity.
2.9. Statistical analysis
All values are expressed as mean þ S.E.M. Di¡er-
ences between control and mimosine-treated groups
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were assessed by the Student’s t-test (SigmaStat) for
signi¢cance of di¡erences between data sets. Signi¢-
cant di¡erences among groups were de¢ned by a
probability of less than 0.05.
3. Results
3.1. E¡ect of mimosine on DNA synthesis
An assay to determine incorporation of
[3H]thymidine in cardiac ¢broblasts was used for de-
tection of the e¡ect of mimosine on cardiac ¢broblast
proliferation. Mimosine from 100^600 WM was ad-
ministered in cultured cardiac ¢broblasts for 24 h.
DNA synthesis assay indicated that mimosine inhib-
its DNA synthesis in a dose-dependent manner and
becomes e¡ective at the dose of 150 WM (Fig. 1). The
[3H]thymidine incorporation was less than 10% of
control values at presence of 200 WM mimosine
(10% serum) and at 400 WM mimosine in serum-
free culture conditions. In order to examine the cy-
totoxicity of mimosine, lactate dehydrogenase (LDH)
activity in the culture medium was monitored after
the administration of mimosine at di¡erent doses.
The results indicated that at concentrations of
25^800 WM, mimosine had no signi¢cant e¡ect on
LDH activity in cultured primary ¢broblasts (Fig. 2).
3.2. E¡ect of mimosine on (1) immunoreactive
mature collagen and (2) monomeric procollagen
synthesis
Immunocytochemical staining of cultured ¢bro-
blasts using a primary antibody for mature type I
collagen showed that the amount of immunoreactive
trimeric collagen was markedly decreased after treat-
ment with 200 WM mimosine for 24 h in serum-free
conditions (Fig. 3A,C). The localization of ¢broblast
nuclei (Hoechst stain) were provided for each respec-
tive ¢eld in Fig. 3B,D. Type I ¢brillar collagen mol-
ecules are revealed by the relatively bright staining
within primary ¢broblasts. In a parallel series of
studies, monomeric procollagens were detected
(SP1.D8 antibody) in adult ¢broblasts prior to and
after mimosine treatment under exactly the same
conditions as speci¢ed above (Fig. 3E,G), and ¢bro-
blast nuclei were speci¢cally labeled for each ¢eld
(Fig. 3F,H). In direct contrast to the pattern of ma-
ture collagen staining, an apparent marked increase
in the immunoreactive procollagen was noted in
those ¢broblast cultures treated with mimosine.
3.3. E¡ect of mimosine on collagen secretion from
¢broblasts in culture: hydroxyproline assay
Determination of hydroxyproline content in pro-
tein derived from the media of cultured ¢broblasts
indicated that collagen deposition by cultured ¢bro-
blasts was signi¢cantly reduced in the presence of
Fig. 1. Dose-dependent inhibition of DNA synthesis associated
with mimosine treatment. DNA synthesis was determined by in-
corporation of [3H]thymidine after adult cardiac ¢broblasts
were treated with di¡erent doses of mimosine for 24 h. Data
are expressed as percentage of control [3H]thymidine incorpora-
tion (mean þ S.E.M., n = 6 experiments per point).
Fig. 2. The dose-dependent e¡ect of mimosine on LDH release
in ¢broblast culture medium. Cardiac ¢broblasts were treated
with di¡erent doses of mimosine for 24 h. Data are expressed
as mU/ml (mean þ S.E.M., n = 6 experiments per point).
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mimosine when compared to non-treated ¢broblasts
(Fig. 4). Our combined results (Figs. 3 and 4) in-
dicate that mimosine treatment of primary cardiac
¢broblasts was associated with a signi¢cant inhibi-
tion of the production and secretion of mature
¢brillar collagen molecules in adult cardiac ¢bro-
blasts.
3.4. Quanti¢cation of the e¡ect of mimosine on
procollagen type I production
The intracellular accumulation of type I procolla-
gen was detected by Western blot using a monoclo-
nal antibody (SP1.D8) speci¢c to the amino terminal
cleavage site of procollagen type I. The upper panel
in Fig. 5 shows a representative Western blot indica-
tive of the 160 kDa procollagen type I band detected
by SP1.D8 monoclonal antibody. The lower panel
illustrates the relative densitometric quanti¢cation
of type I procollagen proteins. Our results indicate
that 200 WM mimosine treatment was associated with
a signi¢cant increase in the accumulation of type I
procollagen from 4.14 þ 0.27 to 10.19 þ 0.37 arbitrary
units after 24 h treatment with mimosine in serum-
free conditions.
3.5. E¡ect of mimosine on mRNA abundance of
collagen and prolyl 4-hydroxylase
The steady state mRNA levels for collagen type I,
Fig. 3. Immunohistochemical localization of mature collagen type I and procollagen. Cardiac ¢broblasts were treated with vehicle or
mimosine (200 WM) for 24 h. Cells were ¢xed and stained with rabbit anti-human type I collagen antibody (A,C) or a monoclonal
antibody against procollagen (SP1.D8) (E,G). The micrographs in B, D, F and H represent nuclei of cardiac ¢broblasts in A, C, E
and G, respectively. Magni¢cation, U400.
Fig. 4. The e¡ect of mimosine on ¢broblasts mediated hydroxy-
proline production. Adult cardiac ¢broblasts were treated with
200 WM mimosine for 24 h. Data are expressed as Wg/mg pro-
tein (mean þ S.E.M., n = 6 experiments per point). *P6 0.05 vs.
control.
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type III, K-prolyl 4-hydroxylase, and L-prolyl 4-hy-
droxylase was determined by Northern analysis. The
left panel of Fig. 6 depicts a representative Northern
blot showing collagen type I, type III, K-prolyl 4-hy-
droxylase, L-prolyl 4-hydroxylase and GAPDH. The
ratio of each target gene to GAPDH was calculated
and plotted as illustrated in Fig. 6 (right panel). The
results indicate that 200 WM mimosine has no e¡ect
on either type III collagen, K-prolyl 4-hydroxylase,
or L-prolyl 4-hydroxylase mRNA abundance after 24
h treatment when compared with non-treated cardiac
¢broblasts. In contrast, type I collagen mRNA abun-
dance was signi¢cantly decreased by 17.39% after
mimosine treatment (Fig. 6).
3.6. E¡ect of mimosine on MMP activity
The status of ¢broblast-mediated collagen degra-
dation was obtained via examination of MMP activ-
ity using gelatin zymography. The upper panel of
Fig. 7 shows a representative zymographic gel. Two
gelatinolytic bands detected were MMP-2 (72 kDa)
and MMP-9 (92 kDa). The densitometric plot shown
in the bottom panel demonstrated that mimosine had
no e¡ect on MMP-2 activity, but was associated with
a signi¢cant increase of MMP-9 activity when com-
pared with non-treated cardiac ¢broblasts.
Fig. 5. E¡ect of mimosine (200 WM, 24 h treatment) on intra-
cellular procollagen type I concentration in cultured cardiac ¢-
broblasts. Procollagen was detected using a monoclonal anti-
body speci¢c to the amino terminal cleavage site (SP1.D8).
Upper panel : Western blot showing procollagen (160 kDa).
Lower panel : quanti¢cation of Western blot by densitometry
(mean þ S.E.M. of four experiments). *P6 0.05 vs. control.
Fig. 6. E¡ect of mimosine on collagen type I (Coll I), collagen
type III (Coll III), K-prolyl 4-hydroxylase (K-PH), and L-prolyl
4-hydroxylase (L-PH) mRNA abundance. Cardiac ¢broblasts
were treated with 200 WM mimosine for 24 h. Left panel : auto-
radiographs showing Coll I, Coll III, K-PH, L-PH and glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH). Right panel :
quanti¢cation of autoradiographs by densitometry. Results are
expressed as targeted gene mRNA to GAPDH mRNA ratios
(mean þ S.E.M. of three experiments). *P6 0.05 vs. control.
Fig. 7. E¡ect of mimosine on matrix metalloproteinase (MMP)
activity. Cardiac ¢broblasts were treated with 200 WM mimosine
for 24 h. Upper panel: zymography showing MMP-2 and
MMP-9 as indicated by arrow. Lower panel: quanti¢cation of
MMP-2 and MMP-9 by densitometry (mean þ S.E.M. of three
experiments).
BBAMCR 14386 11-11-98
H. Ju et al. / Biochimica et Biophysica Acta 1448 (1998) 51^60 57
4. Discussion
Results from both experimental and clinical stud-
ies have shown that cardiac collagen production is
increased in hypertension and post-myocardial in-
farct hearts [2,28]. Hyperplasia of cardiac ¢broblasts
and elevated collagen production by these cells oc-
curs in response to mechanical stretching of cells and
by growth factor stimulation [27,28]. Growth factors
play an important role in the regulation of cardiac
¢broblast replication and collagen production; plate-
let-derived growth factor (PDGF), ¢broblast growth
factor 2 (FGF-2), and angiotensin II (AII) have been
shown to stimulate the replication of cultured cardiac
¢broblasts [29]. There is signi¢cant redundancy for
the modulation of collagen expression insofar as
transforming growth factor L (TGF-L), insulin-like
growth factor (IGF), PDGF, FGF-2, AII, and endo-
thelin may all stimulate an increase in the production
of collagen by cardiac ¢broblasts [30]. Thus treat-
ment targeting only one of the above hormonal sys-
tems may not be e¡ective in inhibiting overall cardiac
¢broblast proliferation and collagen production. As
prolyl 4-hydroxylase serves as a common pathway
for the regulation of collagen production, this study
addressed the e¡ect on collagen production via in-
hibition of prolyl hydroxylation by mimosine, an in-
hibitor of this enzyme. We found that mimosine
treatment was associated with discoordination in col-
lagen metabolism, insofar as elevated collagen pro-K
type I synthesis occurred in parallel with diminished
secretion of mature trimeric collagens to the culture
medium by adult cardiac ¢broblasts, as was indicated
by hydroxyproline content in proteins derived from
the medium.
We have also demonstrated an inhibitory e¡ect of
mimosine on replication of cardiac ¢broblasts as in-
dicated by DNA synthesis analysis. This e¡ect was
not mediated by drug cytotoxicity in the given exper-
imental condition because at concentrations of
25^800 WM, mimosine does not increase the release
of LDH. This is consistent with results shown in a
previous study performed in cultured smooth muscle
cells [14] and this suggests that this agent is well
tolerated by cultured cells. As mimosine treatment
of ¢broblasts inhibited net collagen secretion, it is
likely that prolyl hydroxylation is a critical point
for net collagen production and secretion by these
cells. Furthermore, we have shown that mimosine
treatment was associated with reduced steady-state
mRNA abundance of collagen type I, but was asso-
ciated with only modest e¡ects on collagen type III,
as well as K- and L-prolyl 4-hydroxylase mRNAs in
¢broblasts. As we have previously noted, discoordi-
nate expression of ¢brillar collagen mRNAs and pro-
teins in vivo, the disparity between the magnitude of
reduction in secreted type I collagens and the alter-
ation of collagen type I mRNA abundance was not
surprising [31]. Rather, the current results support
the hypothesis that post-translational processing of
collagen pro-K type I monomers is crucial for regu-
lation of net collagen deposition by ¢broblasts, as
opposed to transcriptional or translational regulation
of the monomeric molecules. Hydroxylation by prol-
yl 4-hydroxylase requires ascorbic acid, Fe2, 2-oxo-
glutarate and O2 as co-factors for e⁄cient catalysis
of the reaction [9]. The protein-bound metal atom at
the active site mediates hydroxylation via the transfer
of an oxygen atom. It has been proposed that mim-
osine chelates the metal ion at active site of prolyl
4-hydroxylase via a 3-hydroxy-4-keto moiety [15].
Our previous work has revealed that an increased
expression of immunoreactive prolyl 4-hydroxylase
in remnant heart post-MI may be a major mecha-
nism for increased deposition of collagen [31]. Inhibi-
tion of elevated protein concentration of cardiac
prolyl 4-hydroxylase was associated with chronic
AII receptor type I antagonism (losartan), and this
therapy was positively correlated to a reduction in
total collagen protein concentration (cardiac ¢brosis)
in ventricular tissue from post-MI hearts. It was sug-
gested that the regulation of prolyl 4-hydroxylase
expression in post-MI rat hearts is a major mecha-
nism for the control of net cardiac collagen deposi-
tion [31]. An additional regulatory control point for
modulation of apparent collagen output from ¢bro-
blasts is that of collagen removal from the extracel-
lular space via the action of MMPs. As MMP-9 ac-
tivity was induced in the presence of mimosine, it is
possible that increased removal of ¢brillar collagens
by this zymogen could account for the reduction in
immunoreactive collagen type I. On the other hand,
the signi¢cant reduction of medium hydroxyproline
under these conditions does not support this assump-
tion, as all hydroxyproline residues, i.e. from se-
creted, degraded or intact ¢brillar collagen molecules
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are detected. Thus reduced collagen synthesis, rather
than increased degradation, is the likely mechanism
for reduced net collagens in the culture media in the
presence of mimosine.
To date, there is no known treatment that is com-
pletely e¡ective for attenuating cardiac ¢brosis in the
clinical setting however the current results provide
evidence for a putative, novel therapeutic target to
regulate of the synthesis and deposition of collagen.
Whether the antiproliferative and anti¢brotic proper-
ties of mimosine are major factors controlling car-
diac ¢broblast-mediated ¢brosis in speci¢c etiologies
of heart disease in vivo remains unexplored. In addi-
tion, further studies need to be conducted concerning
the possible side e¡ects of mimosine, such as those
caused by the inhibition of hydroxylation and alter-
ation of cellular DNA synthesis before the e⁄cacy of
this agent or other related agents can be evaluated.
The design of new agents with greater selectivity for
prolyl hydroxylase and for heart tissue is an avenue
for further investigation in the management of car-
diac ¢brosis.
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